Research & Scholarship
Protein formulation and stability
Compatibility of drugs with drug delivery devices
Braun LJ, Eldridge AM, Cummiskey J, Arthur, K, and Wuttke D. The role of adjuvant in mediating antigen structure and stability. J Pharm Sci. (2012) 101 1391-1399. [Epub 2011 Dec 28. doi: 10.1002/jps.23039] PMID: 22213631.
Clapp T, Siebert P, Chen, D, and Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci. (2011) 100 388-401. [Epub 2010 Aug 25, doi: 10.1002/jps.22284] PMID 20740674.
Jezek J, Chen D, Watson L. Crawford J, Perkins S, Tyagi A, and Jones-Braun L. A heat-stable hepatitis B vaccine formulation. Human Vaccines (2009) 5(8) 529-535. [Epub 2009 Aug 1] PMID 19556877.
Braun LJ, Jezek J, Peterson S, Tyagi A, Perkins S, Sylvester D, Guy M, Lal M, Priddy S, Plzak H, Kristensen D, and Chen D. Characterization of a thermostable hepatitis B vaccine formulation. Vaccine (2009) 27 4609-4614 [Epub 2009 June 11, doi: 10.1016/j.vaccine.2009.05.069] PMID 19523912.
Braun LJ, Tyagi A, Perkins S, Carpenter J, Sylvester D, Guy M, Kristensen D, and Chen D. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine (2009) 27 72-79 [Epub 2008 Oct 28, doi: 10.1016/j.vaccine.2008.10.027]. PMID 18973782.
Chen D, Tyagi A, Carpenter J, Perkins S, Sylvester D, Guy M, Kristensen DD, and Braun LJ. Characterization of the freeze sensitivity of a hepatitis B vaccine. Human Vaccines (2009) 5 26-32. [Epub 2009 Jan 24]. PMID 18971625.
Estey T, Vessely C, Randolph TW, Henderson I, Braun LJ, Nayar R, and Carpenter JF. Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. J Pharm Sci (2009) 98 2994-3012. doi: 10.1002/jps.21543. PMID 18781606.
Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, and Carpenter JF. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci (2009) 98 2970-2993. Doi: 10.1002/jps.21498. PMID 18680175.
Jones Braun, L. (2012, June) Formulation and Process Impacts of Adjuvants. IBC’s 3rd Annual International Forum: Vaccine Production Summit. San Francisco, CA.
Jones Braun, L. (2012, March) Interactions between antigen and adjuvants: Implications for formulation. New Cells, New Vaccines VI, Wilmington, DE.
Jones Braun, L. (2012, January) Vaccines then and now: Are we any closer to a novel product? 16th Annual Drug Delivery Partnerships Conference, Las Vegas, NV.
Jones Braun, L. (2011, May) Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. AAPS National Biotechnology Conference, San Francisco, CA.
Jones Braun, L. (2010, Nov.) Stability of proteins at solid surfaces: From aluminum-containing adjuvants to zirconia crystals. Short Course lecture at the 8th Globalization of Pharmaceutics Education Network (GPEN) Meeting. Chapel Hill, NC.
Peer-Reviewed Poster Presentations
Clapp T, Munks M, Trivedi R, Kompella UB, and Braun LJ. (2013, Nov.) How Does Freeze-Thaw (FT) Stress of Aluminum-Hydroxide Adjuvant Alone Affect a Recombinant Hepatitis B Surface Antigen (rHBsAg) Vaccine? Poster Presentation at the AAPS Annual Meeting and Exposition, San Antonio, TX.
Clapp T, Kulkarni SS, Kompella UB, and Braun LJ. (2013, Nov.) Mesoporous silica and aluminosilicate particles as novel vaccine adjuvants for a recombinant hepatitis B surface antigen (rHBsAg) vaccine. Poster Presentation at the AAPS Annual Meeting and Exposition, San Antonio, TX.
Clapp T. and Braun LJ. (2010, Nov.) Enhancing the freeze-thaw stability of an aluminum-containing adjuvant. Poster Presentation at the 8th Globalization of Pharmaceutics Education Network (GPEN) Meeting, Chapel Hill, N.C.